Quarterly report [Sections 13 or 15(d)]

Stock-based Compensation - Additional Information (Details)

v3.25.3
Stock-based Compensation - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Feb. 28, 2025
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Jan. 03, 2025
Jun. 07, 2024
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]              
Common stock shares reserved for issuance   6,001,358   6,001,358      
Stock-based compensation expense   $ 4,525,206 $ 148,024 $ 10,776,144 $ 232,155    
Employee Stock Option              
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]              
Number of stock options granted       27,225,823 308,039    
Stock option, strike price   $ 2.34 $ 1.89 $ 2.34 $ 1.89    
Stock option, aggregate grant date fair value   $ 54,700,000 $ 489,108 $ 54,700,000 $ 489,108    
Performance-based options, Granted       2,056,049 45,000    
Performance-based options, weighted average strike price       $ 2.35 $ 2.16    
Restricted Stock [Member] | CorHepta Pharmaceuticals [Member]              
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]              
Stock-based compensation expense   700,000   $ 1,800,000      
Restricted share issued 1,660,222            
Service based vesting shares 996,133            
Performance based vesting shares 166,023            
Service and performance based vesting shares 498,066            
Fair Value Of Restricted Stock Granted       4,900,000      
Unrecognized Compensation Cost   $ 3,200,000   $ 3,200,000      
Two Thousand And Twenty Plan [Member]              
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]              
Plan modification       On June 27, 2025, the stockholders approved an amendment to the 2020 Plan, pursuant to which an automatic evergreen provision was added to provide for an annual increase in January to the number of shares available for issuance under the 2020 Plan and to extend the term of such plan by approximately five years to 2030.      
Number of shares available for grant           31,424,909  
Common stock shares reserved for issuance           27,453,993 2,500,000